Shot to the heart: J&J punts on Capricor & its cardiac stem cell program
How is the stem cell and regenerative medicine biotech sector doing these days and does recent news about specific biotechs such as Capricor suggest issues for the sector more broadly? Capricor had bad...
View ArticleTop 20 predictions for stem cells & regenerative medicine in 2018
Every year I look into my stem cell crystal ball and make predictions for our field including regenerative medicine. Well, I don’t really look into a crystal ball, but I try to use a combination of...
View ArticleStem cell company Intellicell facing new financial wrinkles
It’s difficult to make it as a biotech company and I would say stem cell biotechs in general may have an even rougher time. One such company, Intellicell (Intellicell Biosciences, Inc), is showing a...
View ArticleTop 20 Stem Cell Predictions for 2015
Every year I do a list of top predictions for the coming year for the stem cell and regenerative medicine field. For example, you can see past top 10 predictions lists for 2013 and 2014. What’s in...
View ArticleAt mid-year, how are my top 20 stem cell predictions for 2015 doing?
Each year towards the end of December I make predictions for the coming year as I did for 2015. In the past I usually make a top 10 prediction list, but for this year I made 20 predictions. Admittedly...
View ArticleMesoblast stock on hold: Poll if you expect good or bad news
Adult stem cell biotech Mesoblast ($MESO) is in the unusual situation currently of having its stock on hold. This is a relatively rare event and usually portends some kind of major news. The hold is...
View ArticleWhat is your favorite stem cell/regen med biotech & why?
I’m putting together a list of stem cell and regenerative medicine biotech companies for a blog post, including both public and private. I’ve got a good list already, but want it to be fairly...
View ArticleFDA Regenerative Medicine Advanced Therapy RMAT designations jump to 36
This post includes my updated list of firms/products that have received FDA regenerative medicine advanced therapy designation or RMAT, which are in the public domain. The numbers really jumped in the...
View ArticleStem Cell Biotech Advanced Cell Technology (ACT) gets $35 million
Advanced Cell Technology (ACT; stock symbol ACTC) announced that it has secured $35 million in funding from investment company, Lincoln Park Capital. The press release quotes CEO Gary Rabin: “We are...
View ArticleWhy Lanza and I sold ACT stock
It wasn’t so long ago that I did a post explaining why after following the company for years, I finally bought a small amount of stock in the stem cell biotech, Advanced Cell Technology (ACT; symbol...
View Article